New hope for kids with aggressive brain tumors: pioneering therapy delivered directly to the brain
NCT ID NCT05835687
Summary
This early-stage study is testing a new type of personalized immune therapy called B7-H3-CAR T cells for children and young adults (up to age 21) with brain tumors that have come back or haven't responded to standard treatments. The therapy involves collecting a patient's own immune cells, modifying them in a lab to target a protein on the tumor, and then infusing them directly into the fluid around the brain and spinal cord. The main goal is to find the safest dose of this new treatment.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GLIOBLASTOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
St. Jude Children's Research Hospital
RECRUITINGMemphis, Tennessee, 38105, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.